To reduce dependency on non-European supply chains, France has heavily subsidized the "Bioproduction France" framework. This initiative has transformed French CDMOs into specialists for the end-to-end manufacturing of monoclonal antibodies and recombinant proteins.

Outsourcing to French firms now offers pharmaceutical giants a "Made in Europe" quality guarantee. These services prioritize compliance with the European Medicines Agency (EMA) and use advanced automated systems to ensure that biological products meet the highest purity standards required for international export.